Perrigo (PRGO) Competitors $27.29 -0.14 (-0.51%) As of 12:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PRGO vs. CORT, JAZZ, SUPN, PCRX, OMER, ASMB, NKTR, CPIX, LLY, and JNJShould you be buying Perrigo stock or one of its competitors? The main competitors of Perrigo include Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Omeros (OMER), Assembly Biosciences (ASMB), Nektar Therapeutics (NKTR), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), and Johnson & Johnson (JNJ). These companies are all part of the "pharmaceuticals" industry. Perrigo vs. Its Competitors Corcept Therapeutics Jazz Pharmaceuticals Supernus Pharmaceuticals Pacira BioSciences Omeros Assembly Biosciences Nektar Therapeutics Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson Corcept Therapeutics (NASDAQ:CORT) and Perrigo (NYSE:PRGO) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations. Is CORT or PRGO more profitable? Corcept Therapeutics has a net margin of 19.33% compared to Perrigo's net margin of -4.16%. Corcept Therapeutics' return on equity of 20.40% beat Perrigo's return on equity.Company Net Margins Return on Equity Return on Assets Corcept Therapeutics19.33% 20.40% 16.64% Perrigo -4.16%8.93%3.87% Do insiders and institutionals have more ownership in CORT or PRGO? 93.6% of Corcept Therapeutics shares are held by institutional investors. Comparatively, 95.9% of Perrigo shares are held by institutional investors. 20.5% of Corcept Therapeutics shares are held by insiders. Comparatively, 0.4% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts prefer CORT or PRGO? Corcept Therapeutics presently has a consensus price target of $138.25, suggesting a potential upside of 95.49%. Perrigo has a consensus price target of $33.00, suggesting a potential upside of 20.92%. Given Corcept Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Corcept Therapeutics is more favorable than Perrigo.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corcept Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Perrigo 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 Does the media favor CORT or PRGO? In the previous week, Corcept Therapeutics had 2 more articles in the media than Perrigo. MarketBeat recorded 13 mentions for Corcept Therapeutics and 11 mentions for Perrigo. Corcept Therapeutics' average media sentiment score of 1.06 beat Perrigo's score of 0.93 indicating that Corcept Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Perrigo 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, CORT or PRGO? Corcept Therapeutics has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorcept Therapeutics$675.04M11.11$141.21M$1.1660.96Perrigo$4.37B0.86-$171.80M-$1.31-20.83 Which has more volatility & risk, CORT or PRGO? Corcept Therapeutics has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500. SummaryCorcept Therapeutics beats Perrigo on 13 of the 16 factors compared between the two stocks. Get Perrigo News Delivered to You Automatically Sign up to receive the latest news and ratings for PRGO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRGO vs. The Competition Export to ExcelMetricPerrigoMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$3.75B$10.32B$5.51B$20.47BDividend Yield4.34%2.11%5.38%3.76%P/E Ratio-20.8416.8926.2127.69Price / Sales0.8626.86415.3037.00Price / Cash5.2922.8736.4921.79Price / Book0.863.638.004.52Net Income-$171.80M$233.36M$3.15B$984.47M7 Day Performance2.36%1.45%1.72%3.14%1 Month Performance2.18%3.29%4.63%5.57%1 Year Performance5.04%-11.86%35.87%13.91% Perrigo Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRGOPerrigo4.8577 of 5 stars$27.29-0.5%$33.00+20.9%+4.3%$3.75B$4.37B-20.848,379News CoverageCORTCorcept Therapeutics4.711 of 5 stars$74.28+4.1%$138.25+86.1%+112.2%$7.88B$675.04M64.03300JAZZJazz Pharmaceuticals4.9101 of 5 stars$106.76-0.7%$184.00+72.3%+2.8%$6.46B$4.07B14.232,800Positive NewsSUPNSupernus Pharmaceuticals2.3119 of 5 stars$31.99-0.9%$36.00+12.5%+19.8%$1.79B$661.82M28.82580PCRXPacira BioSciences3.5186 of 5 stars$24.74+2.1%$26.44+6.9%-18.3%$1.15B$700.97M-10.85720Positive NewsOMEROmeros3.684 of 5 stars$3.19-0.6%$18.00+464.3%-24.8%$186.90MN/A-1.20210Analyst ForecastASMBAssembly Biosciences3.512 of 5 stars$17.10-1.7%$33.00+93.0%+33.9%$130.64M$28.52M-2.74100High Trading VolumeNKTRNektar Therapeutics4.6101 of 5 stars$9.54+12.1%$67.50+607.5%+34.4%$118.39M$98.43M-0.99220Analyst RevisionGap DownHigh Trading VolumeCPIXCumberland Pharmaceuticals0.5344 of 5 stars$3.93-9.7%N/A+133.4%$58.79M$37.87M-15.7280Gap DownLLYEli Lilly and Company4.9882 of 5 stars$770.16+1.0%$1,011.79+31.4%-15.1%$729.91B$45.04B62.6747,000Positive NewsJNJJohnson & Johnson4.8511 of 5 stars$151.33+1.0%$170.88+12.9%+6.4%$364.11B$88.82B16.83138,100Positive News Related Companies and Tools Related Companies Corcept Therapeutics Competitors Jazz Pharmaceuticals Competitors Supernus Pharmaceuticals Competitors Pacira BioSciences Competitors Omeros Competitors Assembly Biosciences Competitors Nektar Therapeutics Competitors Cumberland Pharmaceuticals Competitors Eli Lilly and Company Competitors Johnson & Johnson Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PRGO) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perrigo Company plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Perrigo With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
